Mostly Benign/Rarely Metastasizing Soft Tissue Tumor

  • Murray F. Brennan
  • Cristina R. Antonescu
  • Robert G. Maki
Chapter

Abstract

Ossifying fibromyxoid tumor (OFMT) is a very uncommon soft tissue lesion that can occur anywhere in the body but most commonly in the lower extremity. While most tumors are benign, malignant examples may metastasize in more than half of cases [1]. The largest series to date included only typical cases, excluding tumors with other morphologies, and in that series there were no patients who developed metastatic disease. In the few patients that we have observed recurrences, metastases are observed, typically to lung, and local-regional recurrence can be observed in a multifocal “shotgun” pattern around the area of the tumor, as has been observed in patients with epithelioid sarcoma.

Keywords

Sugar Adenoma Radionuclide Sarcoma Imatinib 

References

  1. 1.
    Folpe AL, Weiss SW. Ossifying fibromyxoid tumor of soft parts: a clinicopathologic study of 70 cases with emphasis on atypical and malignant variants. Am J Surg Pathol. 2003;27(4):421–31.PubMedCrossRefGoogle Scholar
  2. 2.
    Folpe AL, Mentzel T, Lehr HA, et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol. 2005;29(12):1558–75.PubMedCrossRefGoogle Scholar
  3. 3.
    Kenerson H, Folpe AL, Takayama TK, et al. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol. 2007;38(9): 1361–71.PubMedCrossRefGoogle Scholar
  4. 4.
    El-Hashemite N, Zhang H, Henske EP, et al. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet. 2003;361(9366): 1348–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Kwiatkowski DJ. Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC). Lymphat Res Biol. 2010;8(1):51–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Martignoni G, Pea M, Reghellin D, et al. Molecular pathology of lymphangioleiomyomatosis and other perivascular epithelioid cell tumors. Arch Pathol Lab Med. 2010;134(1):33–40.PubMedGoogle Scholar
  7. 7.
    Lee JS, Fetsch JF, Wasdhal DA, et al. A review of 40 patients with extraskeletal osteosarcoma. Cancer. 1995;76(11):2253–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Italiano A, Delcambre C, Hostein I, et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol. 2010;21(5):1135–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010;28(5):835–40.PubMedCrossRefGoogle Scholar
  10. 10.
    West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA. 2006;103(3):690–5.PubMedCrossRefGoogle Scholar
  11. 11.
    O’Sullivan C. The psychosocial determinants of depression: a lifespan perspective. J Nerv Ment Dis. 2004;192(9):585–94.PubMedCrossRefGoogle Scholar
  12. 12.
    Overbeek SE, O’Sullivan S, Leman K, et al. Effect of montelukast compared with inhaled fluticasone on airway inflammation. Clin Exp Allergy. 2004;34(9):1388–94.PubMedCrossRefGoogle Scholar
  13. 13.
    Riad S, Griffin AM, Liberman B, et al. Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res. 2004;426:129–34.PubMedCrossRefGoogle Scholar
  14. 14.
    Ghert MA, Abudu A, Driver N, et al. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Ann Surg Oncol. 2005;12(1):10–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Blay JY, El Sayadi H, Thiesse P, et al. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol. 2008;19(4): 821–2.PubMedCrossRefGoogle Scholar
  16. 16.
    Cassier PA, Gelderblom H, Stacchiotti S, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 2012;118(6):1649–55.Google Scholar
  17. 17.
    Brandal P, Panagopoulos I, Bjerkehagen B, et al. t(19;22)(q13;q12) translocation leading to the novel fusion gene EWSR1-ZNF444 in soft tissue myoepithelial carcinoma. Genes Chromosomes Cancer. 2009;48(12):1051–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Antonescu CR, Zhang L, Chang NE, et al. EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosomes Cancer. 2010; 49(12):1114–24.PubMedCrossRefGoogle Scholar
  19. 19.
    Sasaguri T, Tanimoto A, Arima N, et al. Myoepithelioma of soft tissue. Pathol Int. 1999;49(6):571–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Noronha V, Cooper DL, Higgins SA, et al. Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel. Lancet Oncol. 2006;7(3):270–1.PubMedCrossRefGoogle Scholar
  21. 21.
    Strauchen JA. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;347(11):854–5. author reply 854-855.PubMedCrossRefGoogle Scholar
  22. 22.
    Lee IJ, Park DH, Park MC, et al. Subungual glomus tumours of the hand: diagnosis and outcome of the transungual approach. J Hand Surg Eur Vol. 2009;34(5):685–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Ozdemir O, Coskunol E, Ozalp T, et al. Glomus tumors of the finger: a report on 60 cases. Acta Orthop Traumatol Turc. 2003;37(3):244–8.PubMedGoogle Scholar
  24. 24.
    Van Geertruyden J, Lorea P, Goldschmidt D, et al. Glomus tumours of the hand. A retrospective study of 51 cases. J Hand Surg Br. 1996;21(2):257–60.PubMedCrossRefGoogle Scholar
  25. 25.
    McCusick VA. Online Mendelian Inheritance in Man. Glomulovenous malformations; GVM. MIM ID #138000. 2010. http://www.ncbi.nlm.nih.gov/omim/138000. Accessed 25 Nov 2010.
  26. 26.
    Gorlin RJ, Fusaro RM, Benton JW. Multiple glomus tumor of the pseudocavernous hemangioma type; report of case manifesting a dominant inheritance pattern. Arch Dermatol. 1960;82:776–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Happle R, Konig A. Type 2 segmental manifestation of multiple glomus tumors: a review and reclassification of 5 case reports. Dermatology. 1999;198(3):270–2.PubMedCrossRefGoogle Scholar
  28. 28.
    Keefer CJ, Brantley B, DeLozier 3rd JB. Familial infiltrative glomangiomas: diagnosis and treatment. J Craniofac Surg. 1996;7(2):145–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Magliulo G, Parnasi E, Savastano V, et al. Multiple familial facial glomus: case report and review of the literature. Ann Otol Rhinol Laryngol. 2003;112(3):287–92.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Murray F. Brennan
    • 1
  • Cristina R. Antonescu
    • 2
  • Robert G. Maki
    • 3
  1. 1.International Center & Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of PathologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Departments of Medicine Pediatrics, and OrthopaedicsMount Sinai School of MedicineNew YorkUSA

Personalised recommendations